Effectiveness of Hyperbaric Oxygen Therapy in SARS-CoV-2 Pneumonia: The Primary Results of a Randomised Clinical Trial.
Jacek SiewieraKlaudia K BrodaczewskaNatalia JermakowArkadiusz LubasKrzysztof KłosAleksandra MajewskaJacek KotPublished in: Journal of clinical medicine (2022)
Mortality in COVID-19 is mainly associated with respiratory failure, cytokine storm, and macrophage activation. Oxygenation and anti-inflammatory effects of Hyperbaric Oxygen Therapy (HBOT) suggest that it is a promising adjunct treatment for COVID-19. Repeated sessions of HBO with standard COVID-19 therapy were used to reduce the inflammation and increase oxygenation. We evaluated the safety and efficacy of HBOT in avoiding the replacement ventilation and/or ECMO and its effect on the inflammatory process. Twenty-eight moderate-to-severe COVID-19 patients were randomized into control or HBOT group. HBOT patients participated in 5 hyperbaric sessions (60 min). Before and after each session blood gas levels and vital parameters were monitored. Blood samples were collected for extended biochemical tests, blood morphology and immunological assays. There were 3 deaths in the control, no deaths in the HBOT group. No adverse events leading to discontinuation of HBOT were observed and patients receiving HBOT required lower oxygen delivery. We observed decrease in CRP, ferritin and LDH and increase in CD3 in HBOT group compared to control. This study confirmed the feasibility and safety of HBOT in patients with COVID-19 and indicated HBOT can lead to alleviation of inflammation and partial restoration of T cell responses.
Keyphrases
- sars cov
- respiratory failure
- clinical trial
- coronavirus disease
- oxidative stress
- double blind
- open label
- extracorporeal membrane oxygenation
- respiratory syndrome coronavirus
- randomized controlled trial
- end stage renal disease
- mechanical ventilation
- systematic review
- stem cells
- study protocol
- placebo controlled
- chronic kidney disease
- type diabetes
- ejection fraction
- early onset
- risk factors
- acute respiratory distress syndrome
- newly diagnosed
- cardiovascular events
- phase ii
- phase iii
- coronary artery disease
- blood flow
- drug induced